The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19

Hydroxychloroquine Combination Risky for Cancer Patients with COVID-19

May 29, 2020 • By Julie Steenhuysen

  • Tweet
  • Email
Print-Friendly Version / Save PDF

CHICAGO (Reuters)—Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on May 28.

You Might Also Like
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • Hydroxychloroquine for COVID-19 Fails Another Test
  • Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients

The preliminary results suggest doctors may want to refrain from prescribing the decades-old malaria treatment hydroxychloroquine (HCQ) with the antibiotic azithromycin for these patients until more study is done, researchers say.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“Treatment with HCQ and azithromycin were strongly associated with increased risk of death,” Howard Burris, MD, president of the American Society of Clinical Oncology (ASCO), said in a briefing with reporters on the results.

The drug combination initially was thought to help COVID-19 patients, but recent data has cast doubt on the regimen.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The preliminary findings, to be presented this week at ASCO’s virtual scientific meeting, show that the combination may pose a significant risk to cancer patients.

“Taking the combination gives a three times increased risk of dying within 30 days of any cause,” Jeremy Warner, MD, MS, of Vanderbilt University Medical System told reporters.

Pres. Trump, who has often promoted HCQ, in a March 21 tweet called the combination potentially “one of the biggest game changers in the history of medicine.”

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

That was based on a study of fewer than 40 patients in the International Journal of Antimicrobial Agents. More recent studies have shown little or no benefit and increased risks.

Dr. Warner and colleagues analyzed data on 925 patients with cancer who became infected with the coronavirus between March and April. Thirteen percent of the patients died within 30 days of their diagnosis.

Overall, patients whose cancers were actively progressing at the time of infection were five times more likely to die within 30 days than those who were in remission or had no current evidence of cancer.

In the trial, 180 patients were taking HCQ in combination with azithromycin, and 90 were taking HCQ alone.

The U.S. Food and Drug Administration (FDA) has allowed healthcare providers to prescribe the drugs for COVID-19 through an emergency-use authorization, but has not approved the treatment.

The governments of France, Italy and Belgium moved on Wednesday to halt the use of HCQ for COVID-19 patients following a World Health Organization decision on Monday to pause a large trial of the drug due to safety concerns.

Dr. Warner said HCQ alone was not a significant risk factor when adjusting for other risks, noting that the number of individuals taking the drug alone was relatively small.

Pages: 1 2 | Single Page

Filed Under: Drug Updates Tagged With: Cancer, combination therapy, COVID-19, HCQ, Hydroxychloroquine (HCQ)

You Might Also Like:
  • Hydroxychloroquine Tied to Increased Risk of Death in COVID-19 Patients
  • Hydroxychloroquine for COVID-19 Fails Another Test
  • Old Drug, New Interest: COVID-19 Spurs Hydroxychloroquine Supply Concerns for Rheumatic Disease Patients
  • U.S. FDA Warns Against Using Hydroxychloroquine for COVID-19

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)